Successful Use of Etanercept in a Child with Еnthesitis-Аssociated Аrthritis

Aim: demonstration of a clinical case of the successful use of etanercept in a child with еnthesitis-аssociated аrthritis. Key points. Еnthesitis-аssociated аrthritis is one of the clinical variants of juvenile idiopathic arthritis. The initial therapy of еnthesitis-аssociated аrthritis includes nonsteroidal anti-inflammatory drugs (NSAIDs) and non-biological disease-modifying drugs, the ineffectiveness of which is an indication for the appointment of genetically engineered drugs, in particular, the inhibitor of tumor necrosis factor-α etanercept. Conclusion. Currently, for the treatment of еnthesitis-аssociated аrthritis, if the use of NSAIDs and non-biological disease-modifying drugs is ineffective, genetically engineered drugs should be prescribed, in particular etanercept, which allows to achieve drug remission. Keywords: еnthesitis-аssociated аrthritis, etanercept, children.